{
    "id": 4972,
    "name": "myelodysplastic/myeloproliferative neoplasm",
    "source": "DOID",
    "definition": "A myeloid neoplasm that results_in the overproduction of white blood cells. [url:http\\://www.bloodjournal.org/content/114/5/937.long, url:http\\://www.bloodjournal.org/content/127/20/2391, url:http\\://www.bloodjournal.org/content/128/3/462, url:https\\://www.cancer.gov/types/myeloproliferative/patient/mds-mpd-treatment-pdq]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "6470"
    ],
    "termId": "DOID:4972",
    "evidence": [
        {
            "id": 1973,
            "approvalStatus": "FDA approved - On Companion Diagnostic",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Gleevec (imatinib) is FDA approved for myelodysplastic/myeloproliferative cancers that are associated with PDGFRB rearrangements and detected by a companion diagnostic (FDA.gov).",
            "molecularProfile": {
                "id": 471,
                "profileName": "PDGFRB rearrange"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 286,
                    "pubMedId": null,
                    "title": "FDA.gov",
                    "url": "http://www.fda.gov/"
                },
                {
                    "id": 15430,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools"
                },
                {
                    "id": 15459,
                    "pubMedId": null,
                    "title": "Gleevec (imatinib) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021588"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 1596,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a preclinical study, SETPB1 missense mutations conferred a predicted gain-of-function, resulting in transformation of murine myeloid progenitors and increased Pp2ac phosphorylation compared to wild-type SETBP1 in culture, suggesting that Setbp1 may serve as a potential therapeutic target (PMID: 23832012).",
            "molecularProfile": {
                "id": 2731,
                "profileName": "SETBP1 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1599,
                    "pubMedId": 23832012,
                    "title": "Somatic SETBP1 mutations in myeloid malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23832012"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2759,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Pictilisib (GDC-0941) demonstrated efficacy in a mouse model of chronic myelomonocytic leukemia expressing KRAS G12D (ASH Annual Meeting Abstracts 2012 120: 2862).",
            "molecularProfile": {
                "id": 746,
                "profileName": "KRAS G12D"
            },
            "therapy": {
                "id": 749,
                "therapyName": "Pictilisib",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3460,
                    "pubMedId": null,
                    "title": "The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.",
                    "url": "http://abstracts.hematologylibrary.org/cgi/content/abstract/120/21/2862?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=GDC-0941&searchid=1&FIRSTINDEX=0&volume=120&issue=21&resourcetype=HWCIT"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3320,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In multiple clinical studies, nonsense and frameshift mutations in ASXL1 were associated with decreased overall survival in patients with chronic myelomonocytic leukemia (PMID: 26849014, PMID: 23690417, PMID: 20880116).",
            "molecularProfile": {
                "id": 22424,
                "profileName": "ASXL1 inact mut"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3731,
                    "pubMedId": 20880116,
                    "title": "ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20880116"
                },
                {
                    "id": 5278,
                    "pubMedId": 26849014,
                    "title": "Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26849014"
                },
                {
                    "id": 5343,
                    "pubMedId": 23690417,
                    "title": "Prognostic score including gene mutations in chronic myelomonocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23690417"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3323,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "In clinical analyses, mutations in CBL were associated with adverse prognosis in patients with chronic myelomonocytic leukemia (PMID: 26230957, PMID: 23690417, PMID: 19901108).",
            "molecularProfile": {
                "id": 13184,
                "profileName": "CBL mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 3735,
                    "pubMedId": 26230957,
                    "title": "An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26230957"
                },
                {
                    "id": 5343,
                    "pubMedId": 23690417,
                    "title": "Prognostic score including gene mutations in chronic myelomonocytic leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23690417"
                },
                {
                    "id": 5344,
                    "pubMedId": 19901108,
                    "title": "Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19901108"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6169,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).",
            "molecularProfile": {
                "id": 22786,
                "profileName": "ASXL1 wild-type TET2 mut"
            },
            "therapy": {
                "id": 651,
                "therapyName": "Azacitidine",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3740,
                    "pubMedId": 25224413,
                    "title": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25224413"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6170,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, myelodysplastic syndrome patients carrying TET2 mutations and wild-type ASXL1 demonstrated an increased response to treatment with the DNA hypomethylating agents Dacogen (decitabine) or Vidaza (azacitidine) compared to patients with other mutational profiles (65% vs. 44%; OR 2.37, P=0.49) (PMID: 25224413).",
            "molecularProfile": {
                "id": 22786,
                "profileName": "ASXL1 wild-type TET2 mut"
            },
            "therapy": {
                "id": 650,
                "therapyName": "Decitabine",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3740,
                    "pubMedId": 25224413,
                    "title": "TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25224413"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7734,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Jakafi (ruxolitinib) treatment demonstrated safety and preliminary efficacy in chronic myelomonocytic leukemia patients, resulted in a total response rate of 35% (7/20) and reduction of Stat5 signaling (PMID: 26858309).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6461,
                    "pubMedId": 26858309,
                    "title": "A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26858309"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11401,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with myelodysplastic/myeloproliferative cancer and positive for EPHA3 demonstrated senstivity to KB004, showing clinical improvement (PMID: 27736729).",
            "molecularProfile": {
                "id": 27991,
                "profileName": "EPHA3 positive"
            },
            "therapy": {
                "id": 2954,
                "therapyName": "KB004",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9290,
                    "pubMedId": 27736729,
                    "title": "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27736729"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13646,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "EZH2 mutations are associated with a poor prognosis in patients with myelodysplastic/myeloproliferative neoplasm (NCCN.org).",
            "molecularProfile": {
                "id": 27863,
                "profileName": "EZH2 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4972,
                "name": "myelodysplastic/myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00946647",
            "title": "A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1080,
                    "therapyName": "Panobinostat",
                    "synonyms": null
                },
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01164163",
            "title": "INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 907,
                    "therapyName": "Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01398462",
            "title": "Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3081,
                    "therapyName": "CWP232291",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01449058",
            "title": "A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1311,
                    "therapyName": "Alpelisib + Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01746849",
            "title": "Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 795,
                    "therapyName": "Leuprolide",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 2563,
                    "therapyName": "Thiotepa",
                    "synonyms": null
                },
                {
                    "id": 2373,
                    "therapyName": "Palifermin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01822509",
            "title": "Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01829971",
            "title": "A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 1035,
                    "therapyName": "MRX34",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02089230",
            "title": "MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 807,
                    "therapyName": "Binimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02143635",
            "title": "Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2186,
                    "therapyName": "HDM201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02493530",
            "title": "TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 7984,
                    "therapyName": "Ruxolitinib + Umbralisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02530476",
            "title": "Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3189,
                    "therapyName": "Selinexor + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02564536",
            "title": "Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 3177,
                    "therapyName": "Decitabine + Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02727803",
            "title": "Personalized NK Cell Therapy After Chemotherapy and Cord Blood Transplant in Treating Patients With Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9016,
                    "therapyName": "anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan",
                    "synonyms": null
                },
                {
                    "id": 9015,
                    "therapyName": "anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab",
                    "synonyms": null
                },
                {
                    "id": 9014,
                    "therapyName": "anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02749708",
            "title": "Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome",
            "phase": "Phase Ib/II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 7277,
                    "therapyName": "IRX5183",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02795520",
            "title": "Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3951,
                    "therapyName": "OTS167",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02807272",
            "title": "Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 938,
                    "therapyName": "Tipifarnib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02829840",
            "title": "Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",
            "phase": "Phase Ib/II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4464,
                    "therapyName": "Azacitidine + Ponatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02907359",
            "title": "Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 712,
                    "therapyName": "Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 1949,
                    "therapyName": "Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02935361",
            "title": "Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4693,
                    "therapyName": "Atezolizumab + Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03072043",
            "title": "Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5445,
                    "therapyName": "APR-246 + Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03075826",
            "title": "A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1949,
                    "therapyName": "Guadecitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03128034",
            "title": "211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 5714,
                    "therapyName": "Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03238248",
            "title": "Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6164,
                    "therapyName": "Azacitidine + MLN4924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289910",
            "title": "Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5341,
                    "therapyName": "Carboplatin + Topotecan + Veliparib",
                    "synonyms": null
                },
                {
                    "id": 7710,
                    "therapyName": "Carboplatin + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03326310",
            "title": "Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6467,
                    "therapyName": "Azacitidine + Selumetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03397173",
            "title": "TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 651,
                    "therapyName": "Azacitidine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03613532",
            "title": "Venetoclax Added to Fludarabine + Busulfan Prior to Transplant for AML, MDS, and MDS/MPN",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7892,
                    "therapyName": "Busulfan + Fludarabine + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03807063",
            "title": "Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant",
            "phase": "Phase I",
            "recruitment": "Enrolling by invitation",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 6053,
                    "therapyName": "BPX-501",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03862157",
            "title": "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7993,
                    "therapyName": "Azacitidine + MLN4924 + Venetoclax",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03886662",
            "title": "A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3514,
                    "therapyName": "LB-100",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03912064",
            "title": "A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 779,
                    "therapyName": "Ipilimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04016116",
            "title": "Dual PD-1 and JAK2 Inhibition in Hematological Malignancies",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 5227,
                    "therapyName": "Pembrolizumab + Ruxolitinib",
                    "synonyms": null
                },
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04022785",
            "title": "PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8600,
                    "therapyName": "Azacitidine + PLX51107",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04055844",
            "title": "Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1735,
                    "therapyName": "Decitabine + Ruxolitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04187703",
            "title": "5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 1798,
                    "therapyName": "Azacitidine + Decitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04282187",
            "title": "Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9427,
                    "therapyName": "Decitabine + Fedratinib",
                    "synonyms": null
                },
                {
                    "id": 1735,
                    "therapyName": "Decitabine + Ruxolitinib",
                    "synonyms": null
                }
            ]
        }
    ]
}